Bayer is a company known worldwide for its cleaning and agricultural products, medical devices, over-the-counter medications and prescription drugs. Bayer may be best known for making aspirin, but in recent years, the company has also become notorious for the ever-increasing number of court cases filed against it.
It is critical to remain vigilant in order to rebuff efforts to curtail our health freedom. While threats to this freedom are nothing new, we alerted you in June to a very specific threat to homeopathy. The FDA is seeking the authority to ban all homeopathic remedies which are already accepted into the Homeopathic Pharmacopeia of the United States. CFH is allied with another consumer-based organization, Americans for Homeopathy Choice (AHC), in an effort to respond to the FDA thoughtfully and proactively. We need you, the consumer voice of the natural health movement, to tell the FDA that we want access to homeopathic services and treatments as part of a full slate of options for maintaining health and wellness. The FDA can be responsive to what consumers demand, so please share this information with clients, friends and fellow health freedom fighters. Read on for more from AHC.
This is a major announcement and we ask everyone to act ASAP. There are 4 very specific things we need you to do:
- Read our Citizen Petition here.
- Write a comment to the FDA in support of this petition. It’s better if you do this in your own words, so we have provided you with an outline to carry this out. If you can’t write your own, we’d still prefer that you submit something, so we did provide a form letter you can copy/paste and make minor edits.
- Send your Representative and Senators two separate messages. First, send them a copy of that letter you wrote the FDA. Then send them a second message using our form letter. Double-dipping like this gets more messages to Capitol Hill, and that way we can really get their attention!
- Then spread the word far and wide with anyone concerned about limits to health freedom. Please share on Facebook and any other social media platforms you use. Do whatever you can to help inform others about this important issue.
Is Vitamin D the Panacea that has Eluded Big Pharma?
By LINDA BONVIE and BILL BONVIE
“We don’t need to develop a new drug. We already have it.”
That’s how the lead author of a new study of one of our most essential nutrients has summed up his team’s surprising new findings about what it can do for people suffering from what continues to be one of our biggest causes of illness and mortality.
The substance involved is none other than vitamin D3 – and the condition he was referring to was heart disease. Or, to be more specific, damage to the cardiovascular system caused by hypertension, diabetes and other ailments, which this latest research has found can actually be repaired with sufficient amounts of the “sunshine vitamin.”
The research was conducted by Dr. Tadeusz Malinski, an Ohio University professor of advanced chemistry, and two graduate students, and is chronicled in a recent issue of the International Journal of Nanomedicine. If the results sound somewhat hard to believe, perhaps it’s because Big Pharma has been trying for so long to downplay the benefits of natural remedies that it can’t patent.
However, dismissing the results of this study, or the credentials of its lead author, could pose some difficulty for those drug-industry naysayers and their media shills.
That’s because Malinski is no run-of-the-mill college professor. He is the recipient of more than 35 international awards and honors, including the prestigious Maria Curie Medal for biomedical research, the Grand Gold Medal in medicine from the French Society of Arts-Science-Letters, and the 2016 Albrecht J. Fleckenstein Memorial Award by the International Academy of Cardiology for his contributions to fundamental research in that field.
And as Malinski explained in a press release from the university, when observed in clinical settings, many heart-attack victims have been found to be deficient in D3. And while that doesn’t necessarily mean such a deficiency is the direct cause of a heart attack, it increases the risk of having one.
In seeking to identify the medical mechanism responsible, what his team discovered is that D3 has a key role in stimulating production of nitric oxide, which is essential to regulating blood flow and preventing clots from forming, as well as significantly reducing oxidative stress to the cardiovascular system.
And finding that out took some real “in-depth” research, involving the use of nanosensors, about 1,000 times smaller in diameter than human hairs, to determine how vitamin D3 affects key cardiovascular components known as endothelial cells, which line the surface of blood vessels.
“There are not many, if any, known systems which can be used to restore cardiovascular endothelial cells which are already damaged,” noted Malinski. But what his team discovered is that “vitamin D3 can do it.” And that was found to be consistent whether the cells being examined came from Caucasians or African-Americans, who are considered more likely to suffer from vitamin D deficiency, which is now estimated to affect two out of five U.S. adults.
“This is a very inexpensive solution to repair the cardiovascular system,” he added – in other words, one that might not only offer patients a highly effective way to bounce back from a heart attack, but do so without incurring humongous medical bills.
And that perhaps is the crux of why these results aren’t being trumpeted as the lead medical story on all the drug-company-sponsored networks. Because as it turns out, what this first-of-its-kind study has revealed are potentials well beyond the treatment of heart disease, which could negatively impact drug company bottom lines were they to be seriously pursued.
According to Malinski, besides restoring the function of cardiac endothelium following a heart attack, vitamin D therapy could also help to rebuild systems damaged by conditions such as diabetes and atherosclerosis, as well as blood-vessel and capillary malfunctions, hypovolemia, a decrease in the volume of blood plasma, and brain ischemia, an inadequate flow of blood to the brain that can result in stroke or the death of brain tissue.
Such possibilities, as noted in the OU press release, are supported by clinical studies showing that doses of D3 exceeding those currently used for osteoporosis “may be highly beneficial for the treatment of the dysfunctional cardiovascular system.”
Imagine that! Heart disease finally being consigned to the ash heap of medical history, thanks to finding new applications for a natural nutrient that comes to us both in the form of “free” sun exposure (as an old song puts it, “the sunbeams that shine, they’re yours, they’re mine”) and from such foods as egg yolks, oysters and fatty fish like wild-caught salmon and sardines.
And then, of course, there are Vitamin D supplements, which may cost a few bucks, but not anywhere near as much as the drugs you’re likely to be prescribed if you suffer from heart disease or any other health problems due to D deficiencies.
And don’t forget – those heart-healing benefits discovered by Dr. Malinski and his research associates are on top of others that we already knew about, including the strengthening of bones by increasing calcium uptake, as well as warding off a host of diseases and infections, ranging from cancer to the flu by enhancing your immune system.
And that’s not to mention what it does to uplift your spirits and keep depression at bay (yes, John Denver was right about the relationship between sunshine and happiness).
That doesn’t mean you should take vitamin D in unlimited quantities. Supplementation of 2,000 IU a day is considered to be a standard dose, and should be taken during months when you’re getting minimal sun exposure. (4,000 IU is generally regarded as a safe maximum, although the Vitamin D Council recommends you draw the line at 10,000 IU per day for three months and that actual toxicity can result from taking 40,000 or more IU for the same period.)
But from all indications, Vitamin D (or a supplement in the form of D3) could be the real wonder drug researchers have been looking for all these years.
Happy New Year to all of our supporters, friends, allies and readers.
Now that the wrapping paper is gone and noisemakers are stowed, we wanted to send this very brief note looking back at (and forward to) a few issues relating to natural products, health and the environment.
First, there is general uncertainty as to whether the anti-over-regulatory winds in Washington will blow elsewhere in the U.S., especially in states such as New York and California, which have what some would call a hyper-regulatory, or nanny-state, posture in regards to many products, including dietary supplements.
In some cases, strong regulations can serve consumers well—such as with food safety and the environment. In other cases, such as with Prop 65 in California, excess caution paints virtually all products and materials with the “potentially carcinogenic” brush, benefiting no one.
As we enter the New Year, the U.S. Justice Department issued a directive that appears to effectively nullify states’ efforts to legalize marijuana. While we at CFH don’t take a universal position on this plant, as such, we do recognize the botanical’s vital importance for medicinal use. As for other applications, we believe it is up to the states to listen to their citizens, and that it is not up to the U.S. government as it stands on what it perceives to be a moral high ground and attempts to impose its view on all 50 states and all Americans, for that matter.
“In California, we decided it was best to regulate, not criminalize, cannabis,” said California Attorney General Xavier Becerra. “Unlike others, we embrace, not fear, change.” This is an attitude that we can support, in this case and in general.
Second, regarding dietary supplements—on the plus side we have seen growing interest among natural product makers to use clean labels, labels with recognizable, more natural and often sustainable ingredients. Related to this trend is transparency, including such matters as country-of-origin labeling (COOL), which CFH actively supports.
Keeping products honest in all ways fortunately took on greater steam in 2017, and we have seen more clamp-downs on a handful of companies that spike their supplements with drug ingredients.
There has been robust discussion about kratom (an herb in the coffee family, Mitragyna speciosa) and its relative merits, which is good. However, scapegoating one botanical after another from the market under the guise of safety, as we saw with ephedra (Ephedra sinica) some years back, is never a good idea.
The movement to support local farmers, manufacturers, bakers, brewers – and, yes, even candlestick makers – is a welcome wave, although not new, as such. It is, in some ways, merely bringing us back to the days before cargo planes and high-speed trains started to blur the lines between what’s available when and where—in what seasons and in what climates.
Third, speaking of climate and our environment—in recent days we have seen that the U.S. is very close to allowing oil drilling in most U.S. continental-shelf waters, including protected areas of the Arctic and the Atlantic, which is of great potential concern to the integrity of our water and land, and the creatures who rely on them, including all of us.
As we look forward to the rest of 2018, we should encourage the companies whose products we like to maintain their commitment to values we care about and to continue to spread the word about how dietary supplements and natural medicine can help us achieve optimal health and make our lives better.
We sincerely thank you for being involved and for staying informed about the issues that impact our health freedoms.
Your participation is a critical part of our efforts to ensure that the flame of our collective dedication to natural health is never extinguished.
Yours in health,
Vice President, CFH
Citizens for Health regrets the loss of a dear friend and champion of the health freedom movement, Jim Duke. A renaissance man in the truest sense of the word, and as frequent collaborator Steven Foster notes, “His impact and inspiration for the last three generations of all aspects of the herbal community cannot be overstated.” He worked for the USDA’s Agricultural Research Service for almost 30 years as a botanist, developing one of his most enduring legacies, the Phytochemical and Ethnobotanical Databases to which scientists still turn to support their research.
We share here an obituary from the American Botanical Council, a link to his Green Farmacy site, and other items of interest.
Ethnobotanist and Herbal Medicine Advocate Jim Duke Dies at 88
News provided by American Botanical Council
Austin, TEXAS (December 11, 2017) — Jim Duke, PhD, an esteemed ethnobotanist, author, and a co-founder of the American Botanical Council (ABC), died at his home last evening. He was 88 and had been in declining health.
“He was a brilliant, dedicated, funny, and humble man, who earned the admiration, respect, and love of thousands of scientists and herbal enthusiasts,” said Mark Blumenthal, ABC’s founder and executive director. “Jim’s huge body of work, love of plants and people, sense of humor, and generosity of spirit are positive examples for all of us.”
Duke authored hundreds of articles and an estimated three dozen books, both popular and technical. He compiled botanical data from all types of sources for his “Father Nature’s Farmacy” database, and was a humble botanist who preferred to walk barefoot in his extensive medicinal plant garden, or, when possible, the Amazonian rainforest.
Born in Birmingham, Alabama, on April 4, 1929, Duke studied botany at the University of North Carolina, where he received his undergraduate and doctoral degrees in 1955 and 1961, respectively. Postgraduate work took him to Washington University and the Missouri Botanical Garden in St. Louis. It was there where he developed what was, as he put it, “my overriding interest: neotropical ethnobotany.”
Early in Duke’s career with Missouri Botanical Garden, his work took him to Panama, where he penned painstaking technical descriptions of plants in 11 plants families for the Flora of Panama project published in the Annals of the Missouri Botanical Garden. He also studied the ethnobotany of the Choco and Cuna native groups, which culminated in his first book: Isthmian Ethnobotanical Dictionary, a 96-page handbook describing medicinal plants of the Central American isthmus.
In 1963, Jim Duke took a position with the USDA in Beltsville, Maryland. From 1965 to 1971, he worked on ecological and ethnological research in Panama and Colombia for Battelle Memorial Institute. Duke returned to USDA in 1971, where he worked on crop diversification and created a database called the “Crop Diversification Matrix” with extensive biological, ecological, and economic data on thousands of cultivated crops.
His interest in medicinal plants never waned. In 1977, he became chief of the Medicinal Plant Laboratory at USDA’s Agricultural Research Service in Beltsville, and then chief of USDA’s Economic Botany Laboratory. At the time, USDA was under contract with the National Cancer Institute (NCI) to collect plant materials from all over the world for screening for anti-cancer activity. After the program ended in 1981, Jim Duke continued his work at the Germplasm Resources Laboratory. Duke served on the board of the Amazon Center for Environmental Education and Research (ACEER) in the early 1990s, and the nonprofit created a fund in his honor to support its educational programs in 2007. Duke also received the ACEER Legacy Award in 2013.
Duke established the Green Farmacy Garden in Fulton, Maryland, in 1997 as a teaching garden with approximately 300 species of medicinal plants. For several years, Duke hosted the AHPA-ABC HerbWalk as a part of Natural Products Expo East.
“His impact and inspiration for the last three generations of all aspects of the herbal community cannot be overstated,” said Steven Foster, an author, photographer, and collaborator with Duke on multiple books. “He was a renaissance man in the broadest sense.”
Duke is survived by his wife Peggy, daughter Cissy, and son John.
Information regarding services and donations can be found here: A note from the family: Jim Duke’s Legacy
The ABC reports they will be creating a tribute to Jim and his life very soon, and have shared the following, from botanist and long-time Jim Duke collaborator Steven Foster’s personal comments and brief biography of Jim:
It is with great sadness to learn the news of the passing of one of the giants of the herbal movement of the past century, James A. Duke, PhD, who died peacefully on the evening of December 10, 2017.
Jim, as he was known to all, served as one of the founding members of the Board of Trustees of the American Botanical Council. His impact and inspiration for the last three generations of all aspects of the herbal community cannot be overstated.
Perhaps more than any other individual, Jim Duke, personified the coalescing of science with traditional knowledge on medicinal plants, which he freely shared with passion and heart. He was a prolific “compiler” as he referred to himself, of data on medicinal plants, which he shared an estimated three dozen books, both popular and technical.
Jim Duke, was a key figure of the “herbal renaissance,” a phrase coined by Paul Lee, PhD. He was a renaissance man in the broadest sense.
Born in Birmingham, Alabama, on April 4, 1929, Jim Duke was a bluegrass fiddler by age 16, even appearing at the Grand Ole Opry, in Nashville, Tennessee.
An interest in plants was not far behind his interest in music. In 1955, he took a degree in botany from the University of North Carolina. In 1961, the same institution conferred a doctorate in botany upon him. Postgraduate work took him to Washington University and Missouri Botanical Garden in St. Louis. It was there where he developed what was, as he put it, “my overriding interest — neotropical ethnobotany.”
Early in Duke’s career with Missouri Botanical Garden, his work took him to Panama where he penned painstaking technical descriptions of plants in 11 plants families for the Flora of Panama, project, published in the Annals of the Missouri Botanical Garden. During his years in Panama he also studied the ethnobotany of the Choco and Cuna native groups. The Choco are a forest people who lived scattered along rivers, and the Cuna live in villages. Another fruit of these years was his first book — Isthmian Ethnobotanical Dictionary, a 96-page handbook describing medicinal plants of the Central American isthmus.
In 1963, Jim Duke took a position with the USDA in Beltsville, Maryland, focusing on tropical ecology, especially seedling ecology. From 1965 to 1971, he worked on ecological and ethnological research in Panama and Colombia for Battelle Columbus Laboratories. Duke returned to USDA in 1971 where he worked on crop diversification, creating a database called the “Crop Diversification Matrix” with extensive biological, ecological, and economic data on thousands of cultivated crops.
His interest in medicinal plants never waned no matter what unrelated tasks government bureaucrats pushed his way. In 1977, he became Chief of the Medicinal Plant Laboratory at USDA’s Agricultural Research Service in Beltsville, and then Chief of USDA’s Economic Botany Laboratory. At the time, USDA was under contract with the National Cancer Institute (NCI) to collect plant materials from all over the world for screening for anti-cancer activity. After the program ended in 1981, Jim Duke continued his work at USDA as Chief of the Germplasm Resources Laboratory, collecting data and plant material on food crops from around the world.
During the Reagan Administration, he was also charged with the unenviable, and as Jim Duke himself admits, “impossible” task of finding a replacement crop in the Andes for coca, the ancient Inca stimulant and source of its abused alkaloid, cocaine.
Dr. Duke retired from USDA in September of 1995, but retirement was in name only.
For Further Reading:
The herbal drug “should be legal and available for those struggling with addiction,” said Rep. Jared Polis.
By Nick Wing
Members of the U.S. House began circulating two Dear Colleague letters on Wednesday, urging their fellow lawmakers to take a stand against renewed federal efforts to crack down on the herbal drug kratom.
One letter, written by Reps. Jared Polis (D-Colo.) and Dave Brat (R-Va.) and addressed to the Food and Drug Administration, describes kratom as a tool to help fight the opioid epidemic and says the agency has shown “insufficient” evidence to warrant any official warning or action against kratom.
Read the full piece at HuffPost
Although this is coveted as a wonderful bill that is needed in the US so that drugs and medical devices can be fast tracked, if you read the nearly 1000 pages it is clear this is dangerous bill that is has the best interests of the Pharmaceutical industry at heart, NOT its consumers.
Every holiday season, I start to think about how to handle the social events on my holiday calendar. It gets me thinking about what strategies I use to manage my eating during these “potentially” treacherous times.
While our spirits often yearn for changes that give us greater peace, freedom and connectedness, we must embrace the essential paradox that makes change possible.
Emotional Freedom Techniques (EFT) or “Tapping” is a psychological use of the acupuncture meridian points that helps to alleviate physical and emotional problems.